Antitumor Effects News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Antitumor effects. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Antitumor Effects Today - Breaking & Trending Today

15 Health Benefits Of Drinking Pomegranate Juice

Here discover 15 pomegranate juice benefits that can add nourishing components to your daily diet according to research. ....

Punica Granatum , Digestive Health , Heart Health , Research Article , Potent Health , Therapeutic Properties Of Pomegranate , Viruses That Influence Human Health , Antimicrobial Properties , With Nutrients , Transforming Growth Factor , For Your Brain , For The , Urinary Health , Prevent Cancer , Offer Heart Health Benefits , Improve Exercise Endurance , Have Antimicrobial Properties , Help With Obesity , Help Regulate Blood , Help With Infections , Help With Diabetes , Side Effects , Asked Questions , Therapeutic Properties , Potential Benefits , Antitumor Effects ,

Spicing up the fight: Saffron's powerful impact on prostate cancer revealed

Saffron-treated prostate cancer (PCa) cells. ....

United States , Africa Shutterstock , Antitumor Effects , Human Prostate Cancer , Image Credit , Prostate Cancer , Cell Proliferation , N Vitro , Interleukin 2 , Ibonucleic Acid , Western Blot ,

Can Ivermectin Treat COVID mRNA Vaccine Induced Turbo Cancers?

The Expose recently shared another review by Doctor Makis – The Anti Parasitic Drug That is Cheap, Safe & Kills Aggressive Cancers – But Has Not Been FDA Approved. which was about the nati parasitic drug Fenbendazole. ....

South Korea , Shican Zhou , Daeun Lee , Satoshi Omura , J Clin Pharmacol , Mingyang Tang , Sep Intuyod , Jian Liu , William Makis , Kitasato Intitute , Davide Scheim , Kitasato Institute , Animal Health , National Institute Of Health , National Institute , Ivermectin Treat , Induced Turbo , Nobel Prize , Vitro Studies , Vivo Studies , New Application , Inhibiting Colorectal Cancer Cell , Molecular Mechanisms Underlying , Antitumor Effects , Caspase Dependent , Cell Death ,

Driver of responses to checkpoint inhibitors suggests way to improve cancer therapy

Expansion of a diverse subset of T-cell clones influences how patients respond to immune checkpoint inhibitors. ....

Merck Keytruda , Satoshi Ueha , Tokyo University Of Science , Cancer Immunology Research , University Of Tokyo , Tokyo University , Cancer Therapy , Ancer And Disease Research , T Cell Clones , Immune Checkpoint Inhibitors , Antitumor Effects , D8 Tumor Infiltratingt Lymphocytes Clones ,

Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2021 Virtual Congress

Share this article
Share this article
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentz ....

United States , James Dentzer , Guillermo Garcia Manero , University Of Texas Md Anderson Cancer Center , Drug Administration , European Hematology Association , Md Anderson Cancer Center , Curis Inc , Exchange Commission , Department Of Leukemia , Roche Group , Virtual Congress , Biology Translational Research , Chief Executive Officer , Dose Escalation Trial , Novel Oral , Acute Myelogenous Leukemia , Myelodysplastic Syndrome , Interim Report , Antitumor Effects , Human Acute Myeloid Leukemia , Translational Research , Myelodysplastic Syndromes , Orphan Drug Designation , Looking Statements , Securities Litigation Reform Act ,